Cancer remains a common disease with approximately 40% of Americans diagnosed with cancer in their lifetime. Medical advances in the field of oncology have led to an increased life expectancy and a decreased mortality rate. Antineoplastic agents such as taxanes and targeted therapies are indicated in the treatment of many cancers, and their use can be associated with various musculoskeletal complaints and adverse effects. Orthopaedic Surgeons are trained to identify primary bone tumors and metastasis to bones. It is also important for them to have an understanding of the profile of musculoskeletal adverse effects associated with the treatment of the more common neoplasms. This article reviews the current literature on the commonly used chemotherapeutic agents and their associated musculoskeletal effects.
From the Department of Oncology, Yale New Haven Hospital, Yale University (Dr. Sutton and Dr. Knobf), the Department of Orthopaedics and Rehabilitation, Yale New Haven Hospital, Yale University (Dr. Ibe), New Haven, CT, and the Department of Orthopaedic Surgery and Sports Medicine, Hospital for Special Surgery, Stamford, CT (Dr. Sanft).
Dr. Sutton or an immediate family member serves as a paid consultant to Mitek and NBC Sports; serves as an unpaid consultant to SportsMD and ESPN-W; serves as a board member, owner, officer, or committee member of AAOS, American Orthopaedic Society for Sports Medicine, Bassett Society, Ruth Jackson Orthopaedic Society, and ESPN-W. None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Sanft, Dr. Knobf, and Dr. Ibe.